Table of Contents

company-logo

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech Dividend Announcement

• Krystal Biotech does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Krystal Biotech dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Krystal Biotech Dividend History

Krystal Biotech Dividend Yield

Krystal Biotech current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Krystal Biotech stock? Use our calculator to estimate your expected dividend yield:

Krystal Biotech Financial Ratios

P/E ratio107.40
PEG ratio-0.39
P/B ratio6.35
ROE6.34%
Payout ratio0.00%
Current ratio7.97
Quick ratio7.76
Cash Ratio4.18

Krystal Biotech Dividend FAQ

Does Krystal Biotech stock pay dividends?
Krystal Biotech does not currently pay dividends to its shareholders.
Has Krystal Biotech ever paid a dividend?
No, Krystal Biotech has no a history of paying dividends to its shareholders. Krystal Biotech is not known for its dividend payments.
Why doesn't Krystal Biotech pay dividends?
There are several potential reasons why Krystal Biotech would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Krystal Biotech ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Krystal Biotech has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Krystal Biotech a dividend aristocrat?
Krystal Biotech is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Krystal Biotech a dividend king?
Krystal Biotech is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Krystal Biotech a dividend stock?
No, Krystal Biotech is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Krystal Biotech stocks?
To buy Krystal Biotech you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Krystal Biotech stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.